Artiva Biotherapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 29, 2024
ARTV$4.06-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Convertible Preferred Stock and Stockholders’ Deficit
(in thousands, except share data)
| SERIES ACONVERTIBLEPREFERRED STOCK · SERIES BCONVERTIBLEPREFERRED STOCK · COMMON STOCK · ADDITIONALPAID-INCAPITAL · ACCUMULATEDOTHERCOMPREHENSIVEINCOME · ACCUMULATEDDEFICIT · TOTALSTOCKHOLDERS’DEFICIT | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SHARES · AMOUNT · SHARES · AMOUNT · SHARES · AMOUNT | ||||||||||
| Balance at December 31, 2022 | 3,673,148 | $96,767 | 2,487,237 | $119,646 | 792,991 | $— | $11,895 | $— | $(152,591) | $(140,696) |
| Vesting of shares of common stock subject to repurchase, including early exercise | — | — | — | — | 1,425 | — | 7 | — | 7 | |
| Stock-based compensation expense | — | — | — | — | — | — | 1,832 | — | — | 1,832 |
| Net loss | — | — | — | — | — | — | — | — | (16,717) | (16,717) |
| Balance at March 31, 2023 | 3,673,148 | $96,767 | 2,487,237 | $119,646 | 794,416 | — | $13,734 | $— | $(169,308) | $(155,574) |
| Exercise of stock options | — | — | — | — | 1,948 | — | 10 | — | — | 10 |
| Vesting of shares of common stock subject to repurchase, including early exercise | — | — | — | — | 8,835 | — | 8 | — | 8 | |
| Stock-based compensation expense | — | — | — | — | — | — | 2,458 | — | — | 2,458 |
| Unrealized gain on short-term investments | — | — | — | — | — | — | — | 127 | — | 127 |
| Net loss | — | — | — | — | — | — | — | — | (11,284) | (11,284) |
| Balance at June 30, 2023 | 3,673,148 | $96,767 | 2,487,237 | $119,646 | 805,199 | $— | $16,210 | $127 | $(180,592) | $(164,255) |
| Balance at December 31, 2023 | 3,673,148 | $96,767 | 2,487,237 | $119,646 | 809,758 | $— | $18,988 | $308 | $(181,311) | $(162,015) |
| Stock-based compensation expense investments | — | — | — | — | — | — | 1,406 | — | — | 1,406 |
| Unrealized loss on short-term investments | — | — | — | — | — | — | — | (101) | — | (101) |
| Net loss | — | — | — | — | — | — | — | — | (13,963) | (13,963) |
| Balance at March 31, 2024 | 3,673,148 | $96,767 | 2,487,237 | $119,646 | 809,758 | $— | $20,394 | $207 | $(195,274) | $(174,673) |
| Exercise of stock options | — | — | — | — | 4,444 | — | 22 | — | — | 22 |
| Stock-based compensation expense | — | — | — | — | — | — | 1,483 | — | — | 1,483 |
| Unrealized loss on short-term investments | — | — | — | — | — | — | — | (86) | — | (86) |
| Net loss | — | — | — | — | — | — | — | — | (17,843) | (17,843) |
| Balance at June 30, 2024 | 3,673,148 | $96,767 | 2,487,237 | $119,646 | 814,202 | $— | $21,899 | $121 | $(213,117) | $(191,097) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.